We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > bladder cancer

News List

NICE endorses Keytruda for bladder cancer pharmatimes
March 19, 2018
MSD’s Keytruda is the first and only immunotherapy to be recommended for NHS use to treat urothelial carcinoma patients, when prior platinum-containing chemotherapy fails.
Lilly's Cyramza combo boasts strong results in bladder cancer pharmafile
September 12, 2017
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add to the efficacy profile of Cyramza in treating platinum-refractory advanced urothelial carcinoma when used in combination with docetaxel.
Roche’s Tecentriq hits trouble with NICE in bladder cancer pharmaphorum
August 04, 2017
NICE has said Roche’s cancer immunotherapy Tecentriq (atezolizumab) should not receive regular NHS funding as a treatment for bladder cancer in first draft guidance...